Zytiga's Use Expanded for Advanced Prostate Cancer
MONDAY, Dec. 10 (HealthDay News) -- U.S. Food and Drug Administration approval of Zytiga (abiraterone acetate) has been expanded to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy, the agency said Monday.
The drug, designed to decrease production of the male sex hormone testosterone, was first approved in November 2011. Testosterone is thought to spur the growth of prostate tumors, the FDA said in a news release.
Zytiga's approval for the new use followed a clinical study of 1,088 men with advanced, castration-resistant prostate cancer who hadn't received chemotherapy. Men who took Zytiga had a median survival of 35.3 months, compared to 30.1 months among those who took a placebo.
The most common adverse reactions included fatigue, swollen joints, hot flushes, diarrhea, vomiting, cough and high blood pressure.
Zytiga is marketed by Janssen Biotech, based in Horsham, Penn.
To learn more about prostate cancer, visit the U.S. Centers for Disease Control and Prevention.Related Articles
- American Cancer Society Celebrates 100 Years of Progress
May 22, 2013
- Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary
May 21, 2013
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2012 HealthDay. All rights reserved.